Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.

Cell reports - 2 Feb 2016

Duong-Ly Krisna C, Devarajan Karthik, Liang Shuguang, Horiuchi Kurumi Y, Wang Yuren, Ma Haiching, Peterson Jeffrey R

Abstract excerpt

Small-molecule kinase inhibitors have typically been designed to inhibit wild-type kinases rather than the mutant forms that frequently arise in diseases such as cancer. Mutations can have serious clinical implications by increasing kinase catalytic activity or conferring therapeutic resistance. To identify opportunities to repurpose inhibitors against disease-associated mutant kinases, we conducted a large-scale...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to ErbB Receptors

Share to Protein Binding

Share to Protein Kinase Inhibitors

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 26776524
DOI: 10.1016/j.celrep.2015.12.080
PMCID: PMC4740242

Genes

ALK
EGFR
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.PMID 26776524Read ↗

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read ↗

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.Semantic proximity Read ↗

Kinase-targeted cancer therapies: progress, challenges and future directionsSemantic proximity Read ↗

The molecular basis of targeting protein kinases in cancer therapeutics.Semantic proximity Read ↗

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future PerspectivesSemantic proximity Read ↗

A structural atlas of kinases inhibited by clinically approved drugs.Semantic proximity Read ↗

A precision therapy against cancers driven by KIT/PDGFRA mutations.Semantic proximity Read ↗

The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer.Semantic proximity Read ↗

The Clinical Kinase Index: Prioritizing Understudied Kinases as Targets for the Treatment of CancerSemantic proximity Read ↗

Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations.Semantic proximity Read ↗

Protein Kinases as Targets for Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.